4'-deoxydoxorubicinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

4'-deoxydoxorubicinol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	128975
MeSH ID	M0134892

Synonyms (10)

Synonym
5,12-naphthacenedione, 10-((4-aminotetrahydro-6-methyl-2h-pyran-2-yl)oxy)-8-(1,2-dihydroxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-
89780-72-3
7-(4-azanyl-6-methyl-oxan-2-yl)oxy-9-[1,2-bis(oxidanyl)ethyl]-4-methoxy-6,9,11-tris(oxidanyl)-8,10-dihydro-7h-tetracene-5,12-dione
A845310
7-[(4-amino-6-methyl-2-oxanyl)oxy]-9-(1,2-dihydroxyethyl)-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione
4-dol
4'-deoxydoxorubicinol
DTXSID001008968
10-[(4-amino-6-methyloxan-2-yl)oxy]-8-(1,2-dihydroxyethyl)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
epirubicin, ellence

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
"1 of paclitaxel suggests that the drugs might also interact at the pharmacodynamic level."	( Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. Baldini, E; Bocci, G; Conte, PF; Danesi, R; Del Tacca, M; Di Paolo, A; Fogli, S; Gennari, A; Innocenti, F; Salvadori, B, 2002)	0.31

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (28.57)	18.7374
1990's	2 (28.57)	18.2507
2000's	3 (42.86)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (28.57%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (71.43%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.	3.39	1	1	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
hydantoins Hydantoins: Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS.. imidazolidine-2,4-dione : An imidazolidinone with oxo groups at position 2 and 4.	2.03	1	0	imidazolidine-2,4-dione
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	3.81	2	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	5.04	5	2	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
imirestat imirestat: structure given in first source	2.03	1	0
7-deoxyadriamycin aglycone 7-deoxyadriamycin aglycone: adriamycin metabolite; RN given refers to (R)-isomer	1.97	1	0
cremophor el cremophor EL: solvent for Althesin & Propanidid implicated as possible cause of similar adverse effects polyethoxylated castor oil; RN given refers to cpd with unknown MF; see also records for cremophor & cremophor A	3.39	1	1
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	2.03	1	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
7-deoxy-13-dihydroadriamycinone 7-deoxy-13-dihydroadriamycinone: a metabolite of epidoxorubicin	1.97	1	0
esorubicin esorubicin: RN given refers to parent cpd; synthesized deriv of doxorubicin	2.37	2	0
adriamycin aglycone adriamycin aglycone: RN given refers to (8S-cis)-isomer	2.37	2	0

Condition	Relationship Strength	Studies	Trials
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.01	1	0
Breast Cancer [description not available]	4.34	2	2
Breast Neoplasms Tumors or cancer of the human BREAST.	4.34	2	2
Cancer of Kidney [description not available]	1.97	1	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	1.97	1	0
Benign Neoplasms [description not available]	1.96	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1.96	1	0

chemdatabank.com